astaxanthine and Liver-Diseases

Astaxanthin is a carotenoid derived from oxygen-containing non-vitamin A sources and is mainly obtained from marine organisms. Studies have demonstrated that astaxanthin is a natural antioxidant product and it is widely used in the fields of medicine, health-care products and cosmetics. Studies have shown that astaxanthin has important preventive and therapeutic effects on liver fibrosis, non-alcoholic fatty liver, liver cancer, drug and ischemia-induced liver injury, and its mechanism is related to antioxidant and anti-inflammatory activities, and the regulation of multiple signaling pathways. In this review, we discuss the latest data on astaxanthin in the prevention and treatment of liver diseases. An understanding of the structure, source and mechanism of action of astaxanthin in the body would not only provide a theoretical basis for its clinical application but could also have important significance in screening and improving related compounds for the treatment of liver diseases.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Humans; Liver; Liver Diseases; Molecular Conformation; Xanthophylls

Ongoing groundwater arsenic contamination throughout China was first recognized in the 1960s. Groundwater arsenic contamination is a high risk for human and animal health worldwide. Apart from drinking water, diet is the second pathway for arsenic to enter the human body and eventually cause liver injury. Natural astaxanthin extracted from the green algae Haematococcus pluvialis has dominated the nutraceutical market for potential health benefits. Nevertheless, the molecular mechanism underlying the protective effect post astaxanthin against arsenic-induced hepatotoxicity remains largely obscure. In this study, we investigate the effect of natural astaxanthin (derived from Haemotococcus pluvialis) on oxidative stress and liver inflammatory response in rats after the cessation of chronic arsenic exposure. Wistar rats were given astaxanthin (250 mg kg-1) daily for 2 weeks after the cessation of exposure to sodium arsenite (300 μg L-1, drinking water, 24 weeks) by intragastric administration. The results showed that post treatment with astaxanthin attenuated liver injury induced by long-term exposure to arsenic in rats. Most importantly, post treatment with astaxanthin decreased the increasing of inflammatory cytokine NF-κB, tumor necrosis factor-α, interleukin-1β, oxidative stress level, and total arsenic content in livers of rats exposed to arsenic. In addition, post treatment with astaxanthin reversed the increasing of protein levels of alpha-smooth muscle actin and collagen Iα1, which are the activation markers of hepatic stellate cells (HSCs). Collectively, these data demonstrate that post astaxanthin treatment attenuates inflammation response in the liver after the cessation of chronic arsenic exposure via inhibition of cytokine-mediated cell-cell interactions. Daily ingestion of natural astaxanthin might be a potential and beneficial candidate for the treatment of liver damage after the cessation of chronic exposure to sodium arsenite.

Topics: Animals; Arsenic; Cell Communication; Chlorophyta; Cytokines; Groundwater; Hepatic Stellate Cells; Humans; Interleukin-1beta; Liver; Liver Diseases; Male; Oxidative Stress; Plant Extracts; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Water Pollutants, Chemical; Xanthophylls

Astaxanthin (Asta), a xanthophyll carotenoid, has been reported to be a strong antioxidative agent and has anti-inflammatory, antitumor and free radical-scavenging activities. However, inadequate stability and water solubility results in its low bioavailability. This study incorporated Asta into hydrophilic hyaluronan nanoparticles (HAn) to produce Asta-HAn aggregates (AHAna) using an electrostatic field system and investigated the restorative effects of AHAna on retrorsine-CCl₄-induced liver fibrosis in rats in vivo. Transmission electron microscopy (TEM) revealed that the prepared HAn were approximately 15 ± 2.1 nm in diameter and after the incorporation of Asta into HAn, the size increased to 210-500 nm. The incorporation efficiency of Asta was approximately 93% and approximately 54% of Asta was released after incubation for 18 h. Significant reductions in alanine aminotransferase and aspartate aminotransferase levels were observed after the rats were intraperitoneally injected with AHAna. Histopathological findings revealed the greatest reduction in hepatic fibrosis and hepatocyte necrosis in the rats after 2 weeks of intraperitoneal injection with AHAna, which is consistent with the data acquired from serum biochemical analysis. The restorative effects on liver damage displayed by AHAna in vivo demonstrated that Asta aggregated through HAn incorporation exerts therapeutic effects on liver fibrosis and necrosis.

Topics: Animals; Carbon Tetrachloride; Hyaluronic Acid; Liver Cirrhosis; Liver Diseases; Male; Necrosis; Pyrrolizidine Alkaloids; Rats; Xanthophylls

Activation of hepatic stellate cells (HSCs) is critical for liver fibrosis development. Previously, we showed that astaxanthin (ASTX), a xanthophyll carotenoid, has antifibrogenic effects in LX-2 cells, a human HSC cell line. We sought to determine the effect of ASTX on HSC activation, and to identify molecular mediators that are critically involved in the processes. ASTX prevented the activation of mouse primary HSCs, as evidenced by attenuated induction of procollagen type I α1. In human primary HSCs, ASTX also inhibited transforming growth factor β1 (TGFβ1)-induced fibrogenic gene expression. Among 11 classical histone deacetylases (HDACs), difference in HDAC9 mRNA levels between quiescent and activated HSCs was most evident while ASTX significantly decreased the expression of HDAC9 and its transcriptional regulator myocyte enhancer factor 2 (MEF2). ASTX decreased HDAC9 protein as well. In the activated HSCs, ASTX significantly reduced mRNA of HDAC9 and MEF2. Human primary biliary cirrhosis livers showed significantly higher HDAC9 mRNA and protein levels than normal livers, and other liver pathologies also exhibited induced HDAC9 expression. HDAC9 knockdown in LX-2 cells decreased TGFβ1-induced fibrogenic gene expression. In conclusion, ASTX inhibits HSC activation and facilitates HSC inactivation, which is attributable to its inhibitory action on HDAC9 expression.

Topics: Animals; Cells, Cultured; Gene Knockdown Techniques; Hepatic Stellate Cells; Histone Deacetylases; Humans; Liver Diseases; MEF2 Transcription Factors; Mice, Inbred C57BL; Repressor Proteins; Transforming Growth Factor beta1; Xanthophylls

Hepatic ischemia reperfusion (IR) is an important issue in complex liver resection and liver transplantation. The aim of the present study was to determine the protective effect of astaxanthin (ASX), an antioxidant, on hepatic IR injury via the reactive oxygen species/mitogen-activated protein kinase (ROS/MAPK) pathway.. Mice were randomized into a sham, IR, ASX or IR + ASX group. The mice received ASX at different doses (30 mg/kg or 60 mg/kg) for 14 days. Serum and tissue samples at 2 h, 8 h and 24 h after abdominal surgery were collected to assess alanine aminotransferase (ALT), aspartate aminotransferase (AST), inflammation factors, ROS, and key proteins in the MAPK family.. ASX reduced the release of ROS and cytokines leading to inhibition of apoptosis and autophagy via down-regulation of the activated phosphorylation of related proteins in the MAPK family, such as P38 MAPK, JNK and ERK in this model of hepatic IR injury.. Apoptosis and autophagy caused by hepatic IR injury were inhibited by ASX following a reduction in the release of ROS and inflammatory cytokines, and the relationship between the two may be associated with the inactivation of the MAPK family.

Topics: Animals; Antioxidants; Apoptosis; Autophagy; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Inflammation Mediators; Liver Diseases; Male; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Reperfusion Injury; Time Factors; Xanthophylls

The effects of astaxanthin (ASTA) and esterified glucomannan (EMG) on hematological and serum parameters, and liver pathological changes in broilers fed on aflatoxin-B1 (AFB1) contaminated diet were investigated. Two hundred and forty 10-day-old broilers were randomly assigned to one of five dietary treatments including: (i) control diet; (ii) AFB1-contaminated diet; (iii) AFB1 + EGM diet; (iv) AFB1 + ASTA diet; and (v) AFB1 + EGM + ASTA diet. At 35 days old, blood and liver tissue samples were collected for analysis. Results indicated that total white blood cell (WBC) number, hemoglobin (Hgb) concentration, hematocrit (Hct) level, serum alanine amino transferase (AST) and γ-glutamyl transferase (GGT) activities, red blood cell (RBC) number, serum globulin (GLB) and urea nitrogen (BUN) concentrations (P < 0.05) were increased by feeding AFB1-contaminated diet. EMG and ASTA alleviated the alteration of RBC, WBC, Hgb and AST caused by AFB1-contaminated diet. Liver superoxide dismutase (SOD) activity was reduced, while myeloperoxidase (MPO) activity was increased by AFB1-contaminated diet (P < 0.05). Both EGM and ASTA restrained the increase of MPO activity (P < 0.05). Degeneration of the liver tissues was found in broilers fed AFB1-contaminated diet. It suggested that feeding 0.4 mg/kg AFB1-contaminated diet resulted in adverse effects on blood parameters and liver morphology. Dietary addition of EGM addition at 5 g/kg diet, ASTA at 10 mg/kg diet and especially their combination showed positive protection effects on alleviating the alteration of feeding AFB1. The results indicated that supplementation of 5 g EGM/kg diet, 10 mg ASTA/kg diet and their combination could partially or greatly alleviate the adverse effects caused by AFB1, with the EGM+ASTA group receiving the most effective treatment.

Topics: Aflatoxin B1; Animal Feed; Animals; Chickens; Dietary Supplements; Esterification; Food Contamination; Food Microbiology; Hematologic Tests; Liver; Liver Diseases; Mannans; Peroxidase; Superoxide Dismutase; Xanthophylls